IKCS 2025: Advances, Challenges, and Emerging Directions in Kidney Cancer Research and Care.

The 2025 International Kidney Cancer Symposium-North America (IKCS-NA), held November 12-15 in Denver, presented a comprehensive overview of emerging scientific, clinical, and patient-centered advances in renal cell carcinoma (RCC). The meeting highlighted rapid progress across preclinical discovery, biomarker-driven therapy, novel immunotherapeutic platforms, and evolving clinical trial strategies, with particular emphasis on non-clear cell RCC, tumor-immune microenvironment modulation, and precision medicine. Preclinical sessions showcased advances in nanoparticle-based immunotherapy, neoantigen vaccines, STING pathway activation, and metabolic vulnerabilities across rare RCC subtypes. Clinical discussions addressed challenges in oligometastatic disease management, imaging innovation, adjuvant therapy sequencing, and integration of metastasis-directed approaches. Notable oral and poster presentations included first-in-human data on bispecific T-cell engagers, CNS-penetrant targeted therapies, AI-enabled spatial immunobiology, and environmental exposures influencing RCC outcomes. The symposium also underscored critical issues in survivorship, cognitive burden, nutrition, and adolescent and young adult kidney tumors, reflecting a growing commitment to holistic cancer care. Collectively, IKCS 2025 illustrated a field in transition-where biological insight, technological innovation, and multidisciplinary collaboration are converging to redefine the future of kidney cancer research and clinical management.